Analyzing Kalaris Therapeutics (NASDAQ:KLRS) & Erasca (NASDAQ:ERAS)

Kalaris Therapeutics (NASDAQ:KLRS) and Erasca (NASDAQ:ERAS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.

Earnings & Valuation

This table compares Kalaris Therapeutics and Erasca”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44 million	($2.15)	-1.97
Erasca	N/A	N/A	-$124.55 million	($0.93)	-14.76

Erasca is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Kalaris Therapeutics and Erasca’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-72.78%	-43.49%
Erasca	N/A	-35.31%	-29.49%

Risk and Volatility

Kalaris Therapeutics has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500. Comparatively, Erasca has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500.

Institutional & Insider Ownership

66.1% of Kalaris Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of Erasca shares are owned by institutional investors. 68.1% of Kalaris Therapeutics shares are owned by insiders. Comparatively, 14.2% of Erasca shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for Kalaris Therapeutics and Erasca, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1	1	5	1	2.75
Erasca	1	2	7	0	2.60

Kalaris Therapeutics presently has a consensus price target of $15.60, indicating a potential upside of 268.79%. Erasca has a consensus price target of $20.11, indicating a potential upside of 46.47%. Given Kalaris Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Kalaris Therapeutics is more favorable than Erasca.

About Kalaris Therapeutics

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

About Erasca

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.